Advertisement
YOU ARE HERE: LAT HomeCollectionsSkinmedica Inc
IN THE NEWS

Skinmedica Inc

FEATURED ARTICLES
BUSINESS
October 21, 2005 | From Dow Jones/Associated Press
SkinMedica Inc., a Carlsbad, Calif.-based maker of skin-care products, Thursday withdrew its initial public offering registration with the Securities and Exchange Commission because of "market conditions." The company originally filed for an IPO in April and set the terms last month at 5.25 million common shares with an estimated price range of $11 to $13 a share.
ARTICLES BY DATE
BUSINESS
October 21, 2005 | From Dow Jones/Associated Press
SkinMedica Inc., a Carlsbad, Calif.-based maker of skin-care products, Thursday withdrew its initial public offering registration with the Securities and Exchange Commission because of "market conditions." The company originally filed for an IPO in April and set the terms last month at 5.25 million common shares with an estimated price range of $11 to $13 a share.
Advertisement
BUSINESS
June 26, 2004
* Women First HealthCare Inc., a distributor of medicine for women older than 40 that filed for bankruptcy protection in April, won court approval to sell its Vaniqa assets to SkinMedica Inc. for $38.9 million. * MCI Inc. said it would close two call centers and cut 2,000 jobs as revenue declines and government curbs on telemarketing make phone services harder to sell.
BUSINESS
January 23, 2013 | Bloomberg News
Allergan Inc., the Irvine maker of the wrinkle filler Botox, agreed to buy a Silicon Valley pharmaceutical company in a deal valued at $958 million to gain an experimental inhalable migraine treatment. Allergan will pay Map Pharmaceuticals Inc. investors $25 a share, a 60% premium over Tuesday's closing price of $15.58 in New York, the companies said in a statement. The deal was unanimously approved by the boards of both companies and is expected to close late in the first quarter or in the second quarter, the companies said.
BUSINESS
March 3, 2013 | By Stuart Pfeifer, Los Angeles Times
The company: Allergan Inc. Headquarters: Irvine Ticker: AGN Employees: 10,800 Leadership: David E.I. Pyott, chief executive since 1998 Revenue: $5.8 billion in 2012 Net income: $1.1 billion in 2012 Stock price: $108.60 at Friday's close 52-week range: $81.28 to $109.31 P/E ratio: 22.8 based on 2013 estimated earnings Annual dividend: 5 cents, a current yield of about...
HEALTH
April 21, 2008 | Shari Roan, Times Staff Writer
"Restore and renew." "Significantly reduces the loss of cells in the epidermis." "Regenerate cells and repair tissue." The newest skin creams beckon with an air of scientific gravitas, holding out the hope that now, at last, medicine has triumphed over the visible aging process. With tantalizing biological references and understated packaging, the products are among the first on the market to capitalize on the public's insatiable appetite for stem cell technology.
Los Angeles Times Articles
|